Key Takeaways
- The European Commission has made Sanofi's commitments legally binding under EU antitrust rules.
- The case addresses alleged disparagement campaigns in France and Germany against the competing vaccine Fluad.
- Fluad is the only enhanced influenza vaccine for vulnerable patients competing with Sanofi's Efluelda.
According to a European Commission press release published on 14 October 2026, Brussels has rendered legally binding a series of commitments offered by pharmaceutical firm Sanofi. The action follows preliminary EU antitrust concerns regarding alleged disparagement campaigns conducted by Sanofi in Germany and France. These campaigns reportedly targeted Fluad, which is noted as the sole enhanced influenza vaccine for vulnerable patient groups that directly competes with Sanofi's own product, Efluelda. This enforcement action underscores the European Union's ongoing scrutiny of dominant market players within the pharmaceutical sector, particularly concerning practices that could potentially undermine single market dynamics and fair competition. Across the Union, competition authorities are increasingly vigilant regarding commercial strategies that may unfairly restrict consumer choice, impede market access for innovative therapeutics, or disadvantage rival manufacturers of essential public health goods in cross-border European markets. By enforcing these binding commitments, the Commission aims to safeguard fair market conditions for specialised medical treatments, ultimately benefiting healthcare providers, vulnerable citizens, and competing businesses alike. While the immediate antitrust procedure is addressed through these agreed measures, policymakers and industry stakeholders will continue to monitor compliance and broader regulatory developments within the European pharmaceutical landscape as part of upcoming market reviews.
Source: European Commission. Read the original report ↗
Frequently Asked Questions
What prompted the European Commission's action against Sanofi?
The Commission acted on preliminary competition concerns regarding alleged disparagement campaigns in Germany and France against a rival flu vaccine.
Which vaccines are involved in this antitrust case?
The case involves Sanofi's Efluelda and its competitor Fluad, which is the only enhanced flu vaccine for vulnerable patients.